Objective:

To evaluate the efficacy of stapokibart in CRSwNP patients with moderate-to-severe olfactory dysfunction and the impact of baseline characteristics on olfactory recovery.

Approach:

Key Findings:

• Stapokibart led to significant olfactory improvement by Week 2 (P<0.0001).
• At Week 16, 52.5% of patients achieved normosmia.
• Mean objective olfactory score increased from 3.05 ± 2.98 to 11.35 ± 3.73 (P<0.0001).
• Nasal polyp score decreased from 4.03 ± 1.70 to 1.63 ± 1.61 (P<0.001).

Interpretation:

Higher baseline polyp burden correlated with faster early improvement but did not affect the final outcomes of olfactory recovery.

Conclusion:

Stapokibart effectively and rapidly improves olfactory function in CRSwNP patients with moderate-to-severe olfactory dysfunction.

Source

Based on findings from:

Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden

Xiang-Ning Cheng, Liu-Qing Zhou, Yue Zhou, Sha-Zhou Li, Shan Chen, Qing Cheng, Li-Yue Li, Jian-Jun Chen, Tao Zhou. Frontiers In Immunology, 2026.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1858283/full

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.